119 related articles for article (PubMed ID: 22341896)
1. Bis-pyrrolyl-tetrazolyl derivatives as hybrid polar compounds: A case of lipophilic functional bioisosterism with bis-acetamides.
Chatzopoulou M; Bonovolias ID; Nicolaou I; Demopoulos VJ; Vizirianakis IS; Tsiftsoglou AS
Eur J Med Chem; 2012 Apr; 50():75-80. PubMed ID: 22341896
[TBL] [Abstract][Full Text] [Related]
2. Potential antitumor agents. 23.(1) Cytotoxic and differentiating activity of compounds related to hexamethylenebisacetamide.
Andreani A; Rambaldi M; Locatelli A; Andreani F; Lollini PL; Nanni P; Bossa R; Galatulas I
Farmaco; 1993 Nov; 48(11):1503-13. PubMed ID: 8110363
[TBL] [Abstract][Full Text] [Related]
3. Ureido derivatives of pyridine: a new class of inducers of murine erythroleukemia cell differentiation.
Pappas IS; Niopas I; Tsiftsoglou AS
Anticancer Drug Des; 1992 Apr; 7(2):153-61. PubMed ID: 1575888
[TBL] [Abstract][Full Text] [Related]
4. New designed HMBA agents as inducers of erythroleukemia cell differentiation.
Wang H; Zhang S; Zhou J; Zhang J
Chin Med Sci J; 2002 Mar; 17(1):27-31. PubMed ID: 12894881
[TBL] [Abstract][Full Text] [Related]
5. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Richon VM; Webb Y; Merger R; Sheppard T; Jursic B; Ngo L; Civoli F; Breslow R; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5705-8. PubMed ID: 8650156
[TBL] [Abstract][Full Text] [Related]
6. Changes in E2F DNA-binding activity during induced erythroid differentiation.
Richon VM; Venta-Perez G
Cell Growth Differ; 1996 Jan; 7(1):31-42. PubMed ID: 8788031
[TBL] [Abstract][Full Text] [Related]
7. Induced differentiation of murine erythroleukemia cells (MELC) by polar compounds: marked increased sensitivity of vincristine resistant MELC.
Marks PA; Michaeli J; Jackson J; Richon VM; Rifkind RA
Prog Clin Biol Res; 1989; 316B():171-81. PubMed ID: 2616574
[TBL] [Abstract][Full Text] [Related]
8. Hexamethylene bisacetamide-induced differentiation of transformed cells: molecular and cellular effects and therapeutic application.
Marks PA; Rifkind RA
Int J Cell Cloning; 1988 Jul; 6(4):230-40. PubMed ID: 3047266
[TBL] [Abstract][Full Text] [Related]
9. Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide.
Waxman S; Scher BM; Hellinger N; Scher W
Cancer Res; 1990 Jul; 50(13):3878-87. PubMed ID: 2354439
[TBL] [Abstract][Full Text] [Related]
10. Differentiation inducers modulate cytokine signaling pathways in a murine erythroleukemia cell line.
Yamashita T; Wakao H; Miyajima A; Asano S
Cancer Res; 1998 Feb; 58(3):556-61. PubMed ID: 9458105
[TBL] [Abstract][Full Text] [Related]
11. Erythroid potentiating activity of tissue inhibitor of metalloproteinases on the differentiation of erythropoietin-responsive mouse erythroleukemia cell line, ELM-I-1-3, is closely related to its cell growth potentiating activity.
Murate T; Yamashita K; Ohashi H; Kagami Y; Tsushita K; Kinoshita T; Hotta T; Saito H; Yoshida S; Mori KJ
Exp Hematol; 1993 Jan; 21(1):169-76. PubMed ID: 8417953
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide-releasing agents and cGMP analogues inhibit murine erythroleukemia cell differentiation and suppress erythroid-specific gene expression: correlation with decreased DNA binding of NF-E2 and altered c-myb mRNA expression.
Suhasini M; Boss GR; Pascual FE; Pilz RB
Cell Growth Differ; 1995 Dec; 6(12):1559-66. PubMed ID: 9019161
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic effect of butyrate on hexamethylene bisacetamide induced differentiation of murine erythroleukemia cells.
Corin RE; Haspel HC; Peretz AM; Sonenberg M; Rifkind RA
Cancer Res; 1986 Mar; 46(3):1136-41. PubMed ID: 3455880
[TBL] [Abstract][Full Text] [Related]
14. Proteomic analysis of erythroid differentiation induced by hexamethylene bisacetamide in murine erythroleukemia cells.
Petrak J; Myslivcova D; Man P; Cmejlova J; Cmejla R; Vyoral D
Exp Hematol; 2007 Feb; 35(2):193-202. PubMed ID: 17258068
[TBL] [Abstract][Full Text] [Related]
15. Vincristine-resistant erythroleukemia cell line has marked increased sensitivity to hexamethylenebisacetamide-induced differentiation.
Melloni E; Pontremoli S; Damiani G; Viotti P; Weich N; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1988 Jun; 85(11):3835-9. PubMed ID: 3163801
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition and differentiation of C6 glioma cells on treatment with hmba.
Shirsat NV; Kayal JJ; Shaikh S; Mehta A
Cell Biol Int; 2001; 25(7):621-7. PubMed ID: 11448101
[TBL] [Abstract][Full Text] [Related]
17. Synergistic action of activin A and hexamethylene bisacetamide in differentiation of murine erythroleukemia cells.
Yamashita T; Eto Y; Shibai H; Ogata E
Cancer Res; 1990 Jun; 50(11):3182-5. PubMed ID: 2334914
[TBL] [Abstract][Full Text] [Related]
18. Hexamethylene bisacetamide-induced differentiation of Friend virus-transformed murine erythroleukemia cells is associated with parallel changes in casein kinase II and guanine nucleotide exchange factor activities.
Aroor AR; Singh LP; Wahba AJ
Exp Hematol; 1995 Oct; 23(11):1204-11. PubMed ID: 7556531
[TBL] [Abstract][Full Text] [Related]
19. Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells.
Richon VM; Rifkind RA; Marks PA
Cell Growth Differ; 1992 Jul; 3(7):413-20. PubMed ID: 1419904
[TBL] [Abstract][Full Text] [Related]
20. Bcl-XL induction during terminal differentiation of friend erythroleukaemia cells correlates with delay of apoptosis and loss of proliferative capacity but not with haemoglobinization.
Hafid-Medheb K; Poindessous-Jazat V; Augery-Bourget Y; Hanania N; Robert-Lézénès J
Cell Death Differ; 1999 Feb; 6(2):166-74. PubMed ID: 10200563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
